EPKINLYâ„¢ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Subcutaneous EPKINLYâ„¢(epcoritamab) is the first and only bispecific antibody approved in Japan to treat adult…